FindTrial
Sign In

Safety and efficacy of ticagrelor and clopidogrel in STEMI patients with intravenous thrombolysis therapy

Safety and efficacy of ticagrelor and clopidogrel in STEMI patients with intravenous thrombolysis therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-17014113
Enrollment
Unknown
Registered
2017-12-24
Start date
2016-03-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

1:Aspirin Enteric-coated Tablets 300mg+ Ticagrelor Tablets 180mg, recombinant thrombolytic thrombolysis for recombinant urokinase
2:Aspirin Enteric-coated Tablets 300mg+ Clopidogrel Bisulfate Tablets 300mg, recombinant thrombolytic thrombolysis for recombinant urokinase

Sponsors

Department of Cardiology, the Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Acute ST-segment elevation myocardial infarction onset time is less than 12 hours, FMC is expected to first medical contact) to PCI time delay greater than 120min, no thrombolysis contraindications; 2. Incidence of 12-24 hours of progressive ischemic chest pain and at least 2 thoracic lead or limb lead ST-segment elevation> 0.1mV, or hemodynamic instability in patients without direct PCI condition.

Exclusion criteria

Exclusion criteria: 1. thrombolysis contraindications; 2. with direct PCI condition.

Design outcomes

Primary

MeasureTime frame
ECG;Blood;—

Countries

China

Contacts

Public ContactWang Mei

Department of Cardiology, the Second Hospital of Hebei Medical University

wangmei86632@sina.com+86 13313038682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026